Stockreport

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durab [Read more]